ARTICLE | Emerging Company Profile
NeoPhore: Driving neoantigen production via DNA mismatch repair
NeoPhore is making tumor cells more visible to the immune system by triggering neoantigen production
August 1, 2019 11:10 PM UTC
NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.
Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune system regards as non-self -- including T cell therapies and cancer vaccines that either target or deliver the newly formed antigens...